Halozyme Therapeutics, Inc.
HALO NASDAQHealthcare ★★★★★Latest Earnings Above forecast↑
Date
Aug 6, 2026
ET
EPS Est.
1.79
EPS Actual
2.28
Revenue Est.
$402.3M
Revenue Actual
$481M
Next Earnings Report
Date
Nov 2, 2026 · Mon
Time
After-market
Fiscal Period
FY2026 Q3
EPS Est.
2.24
Revenue Est.
$482.3M
Company Overview
Halozyme Therapeutics, Inc. (ticker HALO) is listed on NASDAQ with a market cap of about $12.83B. Its next earnings report (FY2026 Q3) is expected on Nov 2, 2026 (ET), After-market, with consensus EPS of 2.24. In the last 15 reported quarters, EPS beat consensus estimates 12 times.
Actual EPS TrendRecently15Term · Feb 21, 2023 → Aug 6, 2026
Feb 21, 2023Range: -0.24 ~ 2.28Aug 6, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Aug 6, 2026 | -- | 1.79 | Above forecast↑2.28 | $402.3M | $481M |
| May 11, 2026 | -- | 1.55 | 1.60 | $358.6M | $376.7M |
| Feb 17, 2026 | -- | 2.15 | Below forecast↓-0.24 | $435.7M | $451.8M |
| Nov 3, 2025 | -- | 1.63 | 1.72 | $446.5M | $354.3M |
| Aug 5, 2025 | -- | 1.23 | Above forecast↑1.54 | $330.8M | $325.7M |
| May 6, 2025 | -- | 0.95 | Above forecast↑1.11 | $281M | $264.9M |
| Feb 18, 2025 | -- | 1.17 | 1.26 | $285.7M | $298M |
| Oct 31, 2024 | -- | 0.98 | Above forecast↑1.27 | $292.8M | $290.1M |
| Aug 6, 2024 | -- | 0.76 | Above forecast↑0.91 | $208.9M | $231.4M |
| May 7, 2024 | -- | 0.70 | 0.79 | $199.8M | $195.9M |
| Feb 20, 2024 | -- | 0.83 | 0.82 | $231.1M | $230M |
| Nov 6, 2023 | -- | 0.71 | 0.75 | $222.6M | $216M |
| Aug 8, 2023 | -- | 0.63 | Above forecast↑0.74 | $200M | $221M |
| May 9, 2023 | -- | 0.48 | 0.47 | $175.5M | $162.1M |
| Feb 21, 2023 | -- | 0.47 | 0.48 | $192.1M | $181.5M |
Original Filings (SEC)
8-K2026-08-18 ↗
10-Q2026-08-06 ↗
8-K2026-08-06 ↗
8-K2026-07-02 ↗
10-Q2026-05-11 ↗
8-K2026-05-11 ↗
8-K2026-05-07 ↗
8-K2026-04-30 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
